Lipid Nanoparticle Formulations for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The delivery of nucleic acids, such as siRNA and oligonucleotides, faces challenges including enzymatic degradation, immune activation, off-target cytotoxicity, and inefficient endosomal release, limiting their clinical translation due to instability and poor targeting.
Innovation Solution
Lipid nanoparticles comprising a combination of cationic lipids with tertiary and quaternary amine headgroups, peptides like gramicidin, and RNase-degrading agents like proteinase K, which enhance transfection efficiency and stability, while maintaining colloidal stability and targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If cationic lipids with high positive charge are used to enhance nucleic acid binding and cellular uptake, then transfection efficiency is improved, but cytotoxicity increases
Solution Approach 1:
The patent adjusts the charge density parameter of cationic lipids by using mixtures with different headgroup charges (quaternary vs tertiary amines) and controlling the lipid-to-nucleic acid ratio. This optimization allows achieving sufficient transfection efficiency while reducing excessive positive charge that causes cytotoxicity.
Solution Approach 2:
The patent employs composite lipid formulations combining multiple cationic lipid types (quaternary and tertiary amines) with different properties. This composite approach balances the high charge density needed for transfection with reduced cytotoxicity through the complementary characteristics of different lipid components.
2Adaptability or versatility
If nucleic acids are delivered systemically to reach target cells, then therapeutic coverage is improved, but enzymatic degradation by nucleases increases
Solution Approach 1:
The patent uses cationic lipids as intermediary carriers that form stable complexes with nucleic acids. These lipid-nucleic acid complexes protect the nucleic acids from nuclease degradation while enabling systemic circulation and delivery to target cells.
Solution Approach 2:
The lipid formulation creates a protective shell around the nucleic acid payload. This flexible lipid layer shields the vulnerable nucleic acid from enzymatic degradation in the bloodstream while allowing cellular uptake and endosomal release.
3Ease of operation
If LNs are taken up by endocytosis to enter cells, then cellular delivery is improved, but endosomal degradation of encapsulated drug occurs
Solution Approach 1:
The patent utilizes pH-dependent parameter changes of tertiary amine-cationic lipids. These lipids remain neutral at extracellular pH but become positively charged in the acidic endosomal environment, triggering membrane disruption and drug release while maintaining cellular uptake efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid nanoparticle formulations achieve high transfection efficiency, reduce cytotoxicity, and provide stable, targeted delivery of therapeutic agents, including nucleic acids, with improved serum stability and pH-dependent release mechanisms.
Implementation Method 1
Lipid nanoparticles comprising a combination of cationic lipids with tertiary and quaternary amine headgroups
Implementation Method 2
peptides like gramicidin
Implementation Method 3
RNase-degrading agents like proteinase K
Implementation Method 4
pH-dependent release mechanisms
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed.